ARTICLE | Clinical News
EntreMed preclinical data
December 15, 2003 8:00 AM UTC
In a mouse model of angiogenesis, PAR-2 antagonists inhibited angiogenesis in a dose-dependent manner, reaching >75% at the highest doses. In a mouse model of metastatic lung cancer, two PAR-2 antagon...